jRCT2071220117已完成不适用
A Drug-Drug Interaction Study of TAS5315 with CYP3A inhibitor in Healthy Adult Subjects
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- Maximum observed plasma concentration (Cmax) of TAS5315
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 40age old not（—）
- 性别
- All
入选标准
- •Aged 18 or older and younger than 40 years at the time of consent
- •Weigh at least 45.0 kg at the time of screening tests with a body mass index (BMI, weight [kg]/[height {m}]2) ranging from 18.0 to < 25.0 kg/m2
- •Blood pressure and body temperature obtained in screening tests within the following ranges
- •a Systolic blood pressure (in supine position), 90 to 139 mmHg
- •b Diastolic blood pressure (in supine position), 40 to 89 mmHg
- •c Body temperature ranging from 35.0 to 37.4
- •Judged to be healthy by the investigator based on the examination findings (subjective symptoms and objective findings), blood pressure, pulse rate, body temperature, 12-lead ECG, and laboratory tests (hematology test, biochemistry test, and urinalysis) at the time of screening tests
排除标准
- •Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded)
- •Had any severe disease history that may recur during the study period.
结局指标
主要结局
Maximum observed plasma concentration (Cmax) of TAS5315
Maximum observed plasma concentration of TAS5315
Area under the plasma concentration-time curve from the time of dosing to the time of last quantifiable plasma concentration (AUClast) of TAS5315
Area under the plasma concentration-time curve from the time of dosing to the time of last quantifiable plasma concentration of TAS5315
Area under the plasma concentration-time curve from the time of dosing extrapolated to infinity (AUCinf) of TAS5315
Area under the plasma concentration-time curve from the time of dosing extrapolated to infinity of TAS5315
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Drug-Drug Interaction Study of TAS5315 with CYP3A inhibitor in Healthy Adult SubjectsJPRN-jRCT2071220117asermoaddeli Ali20
已完成
不适用
CYP3A and drug transporters activity changes in Thai elderly with or without chronic kidney disease using a microdose cocktail5. Drug transporter1. Chronic kidney disease2. Elderly 3. Pharmacokinetics4. Cytochrome P 4505. Drug transporter1. Chronic kidney disease (CKD)2. Elderly3. Pharmacokinetics (PK)4. Cytochrome P 450 (CYP450)6. OATP1B17. BCRPTCTR20180312002Health Systems Research Institute60
已完成
1 期
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and MidazolamHealthyNCT02233244Celtaxsys, Inc.20
已完成
1 期
A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on IpatasertibHealthy VolunteersNCT03222310Hoffmann-La Roche15
已完成
不适用
Studying the relationship between the CYP3A and CYP2D6 probe dextromethorphan and the pharmackinetics of tamoxifen.10006291breast cancerNL-OMON33769Erasmus MC, Universitair Medisch Centrum Rotterdam37